Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, manufacturing and commercialization of sterile injectable therapies for critical care, oncology and supportive care. Since its founding in 2007 and its initial public offering in 2013, Eagle has built a portfolio of approved products and a late-stage pipeline of novel and generic injectable therapies. The company is headquartered in Woodcliff Lake, New Jersey, and operates an in-house research and development facility alongside strategic manufacturing partnerships to ensure supply continuity and quality control.
The company’s product portfolio includes both branded and generic sterile injectables designed to address acute and life-threatening conditions. Among its key offerings is bendamustine hydrochloride injection for oncology patients, as well as therapies for iron deficiency anemia, acute migraine management and rare metabolic disorders. Eagle leverages a combination of in-licensing agreements and internal development to bring products through clinical trials and into commercial supply, with an emphasis on formulations that offer differentiated delivery advantages or improved administration profiles.
Beyond its marketed products, Eagle maintains a robust pipeline that spans preclinical candidates to late-stage investigational new drug applications. The focus areas include anti-infectives, critical care fluids and supportive oncology regimens. While the company’s operations are primarily concentrated in the United States, it has established distribution arrangements in Canada, selected European markets and parts of Asia to extend patient access. These partnerships allow Eagle to capitalize on regulatory exclusivities and to optimize global supply chains for injectable drugs.
Under the leadership of President and Chief Executive Officer Christopher C. Ashby, Eagle Pharmaceuticals emphasizes operational efficiency, regulatory compliance and targeted product acquisitions. The management team brings together expertise in sterile manufacturing, clinical development and commercialization, positioning the company to pursue both organic growth and strategic in-licensing opportunities. With a dedicated board and seasoned executive suite, Eagle continues to advance its mission of delivering critical care therapies that address unmet medical needs.
AI Generated. May Contain Errors.
Free EGRX Stock Alerts